Phase I Trial of huCART-meso + VCN-01 in Patients with Pancreatic and Ovarian Cancer
Summary
The purpose of this phase I study is to evaluate the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05057715
Study ID: UPCC# 03821, IND #27590
Trial Phase: Phase I
Trial Sponsor: University of Pennsylvania Abramson Cancer Center
Therapies Used in This Trial: VCN-01, huCART-meso cells